{
  "id": "56cf27293975bb303a000003",
  "type": "yesno",
  "question": "Does ziconotide bind to N-type calcium channels?",
  "ideal_answer": "Yes, ziconotide/omega-conotoxin MVIIA blocks N-type calcium channels.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/11279062",
    "http://www.ncbi.nlm.nih.gov/pubmed/16831862",
    "http://www.ncbi.nlm.nih.gov/pubmed/16225359",
    "http://www.ncbi.nlm.nih.gov/pubmed/22608964",
    "http://www.ncbi.nlm.nih.gov/pubmed/20413151",
    "http://www.ncbi.nlm.nih.gov/pubmed/25456079",
    "http://www.ncbi.nlm.nih.gov/pubmed/10666532",
    "http://www.ncbi.nlm.nih.gov/pubmed/15578997",
    "http://www.ncbi.nlm.nih.gov/pubmed/16207099",
    "http://www.ncbi.nlm.nih.gov/pubmed/10834782",
    "http://www.ncbi.nlm.nih.gov/pubmed/20188724",
    "http://www.ncbi.nlm.nih.gov/pubmed/22084632",
    "http://www.ncbi.nlm.nih.gov/pubmed/17063978",
    "http://www.ncbi.nlm.nih.gov/pubmed/16845440",
    "http://www.ncbi.nlm.nih.gov/pubmed/11059665",
    "http://www.ncbi.nlm.nih.gov/pubmed/21577088",
    "http://www.ncbi.nlm.nih.gov/pubmed/10666519",
    "http://www.ncbi.nlm.nih.gov/pubmed/15209164",
    "http://www.ncbi.nlm.nih.gov/pubmed/9315745",
    "http://www.ncbi.nlm.nih.gov/pubmed/25446431",
    "http://www.ncbi.nlm.nih.gov/pubmed/22428804",
    "http://www.ncbi.nlm.nih.gov/pubmed/17199507",
    "http://www.ncbi.nlm.nih.gov/pubmed/10436454",
    "http://www.ncbi.nlm.nih.gov/pubmed/22188924",
    "http://www.ncbi.nlm.nih.gov/pubmed/21992243",
    "http://www.ncbi.nlm.nih.gov/pubmed/19300539",
    "http://www.ncbi.nlm.nih.gov/pubmed/10547097"
  ],
  "snippets": [
    {
      "text": "Since this region partially overlaps with residues previously implicated in block of the channel by omega-conotoxin GVIA, we assessed the effects of mutations in the putative EF hand domain on channel block by omega-conotoxin GVIA and the structurally related omega-conotoxin MVIIA. Both of the toxins irreversibly block the activity of wild type alpha(1B) N-type channels. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11279062",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Despite their high sequence homology, the peptide neurotoxins omega-conotoxin MVIIA and MVIIC selectively block N- and P/Q-type calcium channels, respectively. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9315745",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Binding assay for both N- and P/Q-type calcium channels showed that amino acid residues restricted to the N-terminal half are important for the recognition of N-type channels, whereas essential residues for P/Q-type channel recognition are widely spread over the whole omega-conotoxin molecule.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9315745",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ziconotide is a novel peptide that blocks the entry of calcium into neuronal N-type voltage-sensitive calcium channels, preventing the conduction of nerve signals.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16207099",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ziconotide is a selective, potent and reversible blocker of neuronal N-type voltage-sensitive calcium channels (VSCCs).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10666532",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The therapeutic benefit of ziconotide derives from its potent and selective blockade of neuronal N-type voltage-sensitive calcium channels.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16225359",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10666532",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10834782",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16207099",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Thus, ziconotide is the first of a new class of agents--N-type calcium channel blockers, or NCCBs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16225359",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ziconotide, formerly known also as SNX- 111, represents a new class of agents, the N-type calcium channel blockers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16845440",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The selective N-type calcium channel blocker ziconotide ameliorates severe chronic pain but has a narrow therapeutic window and requires intrathecal administration.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25456079",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A selective N-type calcium channel inhibitor, ziconotide (Prialt), is a neuroactive peptide recently marketed as a novel nonopioid treatment for severe chronic pain.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16831862",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "As the clinically available analgesics, pregabalin (alpha2delta-subunit calcium channel ligand), ziconotide (N-type calcium channel blocker), mexiletine (sodium channel blocker), and duloxetine (serotonin and norepinephrine reuptake inhibitors) were evaluated in these neurochemically-induced allodynia models.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20188724",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The present investigation was designed to assess the safety and analgesic efficacy of ziconotide, a new N-type calcium channel blocker, when administered intrathecally to patients with acute postoperative pain.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10834782",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inhibition of the N-type calcium channel by intrathecal administration of the channel-specific blocker omega-conotoxin MVIIA (ziconotide) is efficacious in the treatment of severe chronic pain.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17199507",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ziconotide is a powerful analgesic drug that has a unique mechanism of action involving potent and selective block of N-type calcium channels, which control neurotransmission at many synapses.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19300539",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In conclusion, present findings provide implication that the spinal anti-nociceptive mechanistic site of pregabalin is different from that of ziconotide, mexiletine, and duloxetine, and pregabalin could have a broader anti-nociceptive mechanism other than N-type calcium channel blockade.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20188724",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ziconotide (SNX-111), a selective blocker of neuronal N-type voltage-sensitive calcium channels, is antinociceptive when it is administered intrathecally.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10666519",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10666519",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A state-dependent Ca(V)2.2 inhibitor may provide an improved therapeutic window over ziconotide, the peptidyl Ca(V)2.2 inhibitor used clinically. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22188924",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There is also human validation data from ziconotide, the CaV2.2-selective peptidyl inhibitor used clinically to treat refractory pain. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25446431",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A selective N-type calcium channel inhibitor, ziconotide (Prialt), is a neuroactive peptide recently marketed as a novel nonopioid treatment for severe chronic pain. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16831862",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The neuroprotective effects of intrathecal administration of the selective N-type calcium channel blocker ziconotide in a rat model of spinal ischemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10436454",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020864"
  ],
  "exact_answer": "Yes"
}